Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | F7 | P08709 | 1/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14369641 | 0.93 | OPRM1 (0.39) | TRPM8OPRM1OPRD1OPRK1TSHR | |
| SCHEMBL14369648 | 0.83 | F2 (0.34) | TRPM8KCNH2OPRM1OPRD1OPRK1 | |
| SCHEMBL14178521 | 0.81 | TAS1R3 (0.39) | TSHRMAPT | |
| Trifluoroacetic Acid SCHEMBL4964196 | 0.80 | HRH4 (0.39) | KCNH2OPRM1OPRD1OPRK1 | |
| SCHEMBL4966117 | 0.79 | MAPK14 (0.36) | TRPM8OPRM1OPRD1OPRK1TSHR | |
| SCHEMBL4967356 | 0.79 | KCNH2 (0.34) | KCNH2 | |
| SCHEMBL4965081 | 0.77 | OPRM1 (0.36) | OPRM1OPRD1OPRK1 | |
| SCHEMBL4964601 | 0.74 | OPRM1 (0.57) | OPRM1OPRD1OPRK1TSHR | |
| SCHEMBL14178552 | 0.74 | HTR1A (0.43) | OPRM1OPRD1OPRK1TSHRMAPT | |
| Hydrochloric Acid SCHEMBL4968080 | 0.74 | OPRM1 (0.56) | OPRM1OPRD1OPRK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730140-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-06-25 | — | — | EP | claimed |
| EP-1730140-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-06-25 | — | — | EP | disclosed |
| US-7288543-B2 | For therapy or prophylaxis of obesity and related diseases including eating disorders (bulimia, anorexia nervosa, etc.), diabetes, diabetic complications, diabetic retinopathy, sexual/reproductive disorders, depression, anxiety, epileptic seizure, hypertension, cerebral hemorrhage | ELI LILLY AND COMPANY (US) | 2007-10-30 | — | — | US | disclosed |
| US-20070179129-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179129-A1 | Opioid receptor antagonists | OPRK1, OPRM1, OPRL1 | TRPM8 747/4885KCNH2 612/4885OPRM1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.